Epidermal growth factor receptor (EGFR), representing a promising new therapeutic target in cancer, is highly expressed in most human epithelial carcinomas and is expressed in 89%-100% of the samples collected from NPC patients (6, 7). The gene discussed is EGFR; the disease is nasopharyngeal carcinoma.